Reason for request
Re-assessment of the actual benefit and improvement in actual benefit at the request of the Transparency Committee in accordance with Article R 163-21 of the French Social Security Code
Clinical Benefit
Clinical Added Value
| minor |
In the treatment of chronic hepatitis C due to genotype 1 HCV in patients with compensated liver disease, VICTRELIS in combination with dual therapy with peginterferon alfa and ribavirin provides a minor improvement in actual benefit (level IV) in comparison with this dual therapy. |
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
KmXQ2tWnL1sLHzJa
